98%
921
2 minutes
20
The constitutive androstane receptor (CAR), encoded by the gene, is a nuclear receptor mainly expressed in the liver, where it regulates (xenobiotic) drug and bile acid metabolism, bilirubin clearance and energy homeostasis. CAR has emerged as a promising therapeutic target for diabetes, fatty liver disease and alcoholic liver disease, but it has barely been investigated in the context of sepsis. Since alterations in drug metabolism have been observed in sepsis patients, who may also exhibit increased serum bilirubin and bile acid levels, we hypothesize that CAR function may be impaired during sepsis. Here, we demonstrate that CAR loses its function in the liver during sepsis, as evidenced by a diminished response to its agonist TCPOBOP. We show that mRNA transcription is reduced, mediated by decreased HNF4α binding to the promoter and by downregulation of expression. Additionally, we show that CAR DNA binding is impaired, and we propose that HNF4α may regulate chromatin accessibility of CAR binding sites in sepsis. CAR loss-of-function further causes the downregulation of genes involved in monocarboxylic acid, fatty acid, and xenobiotic metabolism, but induces a hepatic acute phase response, which is beneficial for liver regeneration. However, CAR inhibition with CINPA1 increases sepsis lethality, associated with the further downregulation of these metabolic genes, increased upregulation of the acute phase response, but persistent downregulation of proliferation markers in the liver. Altogether, our study highlights the importance of CAR in sepsis with respect to hepatic metabolism, liver regeneration and survival. Nevertheless, CAR is unlikely to serve as a viable therapeutic target in sepsis, given its rapid downregulation and the lack of a survival benefit from TCPOBOP treatment. Instead, targeting upstream regulators such as HNF4α may represent a more effective approach.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401704 | PMC |
http://dx.doi.org/10.3389/fimmu.2025.1625104 | DOI Listing |
J Dev Behav Pediatr
September 2025
Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston University, Boston, MA.
John is a 12-year-old African-American boy with a Specific Learning Disorder in Reading and Generalized Anxiety Disorder who you are seeing in follow-up at your clinic. Last fall, when John was having an escalation of his anxiety symptoms at school, he enacted the behavior intervention plan (BIP) that had been previously established by his educational team of informing his teacher that he needed to leave the classroom. He then paced the hallway outside of his classroom as a method of coping with the anxiety that he was experiencing.
View Article and Find Full Text PDFCancer Immunol Res
September 2025
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Antibody-based therapies have revolutionized cancer treatment but have several limitations. These include: down-regulation of the target antigen; mutation of the target epitope; or in the case of antibody drug conjugates (ADCs), resistance to the chemotherapy warhead. Since TROP2-targeted therapy with ADCs yields responses in TROP2+ solid tumors but lacks the durability observed with other immunotherapy-based approaches, we developed novel TROP2-targeting chimeric antigen receptor (CAR) T cells as an alternative.
View Article and Find Full Text PDFCancer Res Commun
September 2025
Fred Hutchinson Cancer Center, Seattle, WA, United States.
Metastatic and relapsed osteosarcoma (OS) remains difficult to treat despite advanced surgical techniques, intensified chemotherapy, and targeted therapies. Adoptive immunotherapies such as chimeric antigen receptor (CAR) T cells, are in their nascent stage, but remain a viable therapeutic strategy for patients with aggressive solid tumors such as OS. Folate receptor- (FOLR1) has been functionally implicated in OS pathophysiology, providing rationale as a potential therapeutic target.
View Article and Find Full Text PDFAm J Hematol
September 2025
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) is a life-threatening hyperinflammatory syndrome, and hierarchical management based on a prognostic model is important. The endothelial activation and stress index (EASIX) score has demonstrated prognostic utility in recipients of allogeneic stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy. However, its role in LA-HLH remains unestablished.
View Article and Find Full Text PDFA 52-year-old Myanmar man presented with bilateral progressive painless asymmetrical wrist and finger drop in 1 year without any sensory and sphincter problems. He has hypochromic microcytic anemia diagnosed as Hemoglobin E disease before. However, a serial full blood count revealed thrombocytopenia and a drop in hemoglobin disproportionate to HbE disease.
View Article and Find Full Text PDF